EWTX Edgewise Therapeutics, Inc.
FY2025 10-K
Edgewise Therapeutics, Inc. (EWTX) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Discovery and development of precision small molecule therapies targeting severe skeletal and cardiac muscle diseases
- • New emphasis on sevasemten, an oral fast myosin inhibitor in late-stage trials for Duchenne and Becker muscular dystrophies with recent FDA Fast Track and Orphan Drug designations
Management Discussion & Analysis
- • Net loss $167.8M in 2025 vs $133.8M in 2024, operating expenses rose $32.6M to $191.4M driven by R&D and G&A increases
- • R&D expenses $151.4M vs $127.0M (+19%), led by sevasemten $52.5M, EDG-7500 $18.4M, and new EDG-15400 $7.6M clinical program costs
Risk Factors
- • FDA and EMA regulatory approval risks; lengthy, unpredictable processes may delay product commercialization
- • Macroeconomic risk from U.S. banking sector disruptions; Silicon Valley Bank failure may limit capital market access
Financial SummaryXBRL
Net Income
-$168M
ROE
-32.1%
Total Assets
$553M
EPS (Diluted)
$-1.63
Operating Cash Flow
-$144M
Source: XBRL data from Edgewise Therapeutics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Edgewise Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.